Theratechnologies Inc. announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company?s Audit Committee. Mr. Zwick currently serves as Chief Business Officer at Mirador Therapeutics, which recently launched with over US$400 million in financing to accelerate the next generation of precision medicines for immune-mediated diseases. Previously he was a strategic advisor to Prometheus Biosciences, prior to its sale to Merck in June 2023.

Mr. Zwick has vast executive industry operational experience at companies such as Amarin, InflaRx, Salix Pharmaceuticals and Bausch Health. As part of the team that sold Salix to what is now Bausch Health Companies for US$14.5 billion in 2015, he eventually became Head of Strategy at the Salix business unit responsible for leading all business development transactions, alliance management, strategic planning and portfolio management, playing a key role in the turnaround story of Bausch Health. Over the course of his career, he has successfully led capital raises and the search, evaluation, and execution of a variety of transactions in the life sciences sector.

He holds a Bachelor of Arts and Master of Science from Florida Atlantic University and an M.B.A. from the University of San Francisco. With the appointment of Jordan Zwick, the Company?s Audit Committee will now comprise three independent members including Gerald Lacoste and Frank Holler as Chair.